BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Conditions: Advanced Solid Tumor; Metastatic Solid Tumor; Hormone-receptor-positive Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer Interventions: Drug: BGB-43395; Drug: Fulvestrant; Drug: Letrozole Sponsors: BeiGene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials